Skip to content
Home
About Us
Team
Board
Business Model
Product Pipeline
BRM421 for Dry Eye Syndrome
BRM423 for Corneal Damage Repair
BRM424 for Neurotrophic Keratitis
BRM521 for Treatment of Osteoarthritis
Investors
News
Contact Us
English
Home
About Us
Team
Board
Business Model
Product Pipeline
BRM421 for Dry Eye Syndrome
BRM423 for Corneal Damage Repair
BRM424 for Neurotrophic Keratitis
BRM521 for Treatment of Osteoarthritis
Investors
News
Contact Us
English
選單
2013
BRIM Founded
2014
Series A (USD 4M)
BRM132 In-censed
2015
Series B (USD 26M)
PDSP Platform In-licensed
2016
BRM421 U.S. IND Approval
2017
BRM421 U.S. FIH Study
BRM132 U.S. IND Approval
2018
Series C (USD 6M)
2019
BRM421 U.S. SIH Study Completed
BRM521 Pre-clinical Studies On-going
2020
BRM421 CN Right Licensed to CGP
Subsidiary Ascendo Biotech Formed (raised USD 12M)
Download BRIM's Corporate Overview
Name
Email
I agree to receive further communications from BRIM Biotechnology. By clicking submit below, you consent to allow BRIM Biotechnology to store and process this data.
Send